Conv. Plasma
Nigella Sativa
Peg.. Lambda

All HCQ studies
Meta analysis
Home COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study

Dabbous et al., Archives of Virology, doi:10.1007/s00705-021-04956-9
Jan 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
This study was retracted.
This study includes HCQ and favipiravir.
Dabbous et al., 25 Jan 2021, peer-reviewed, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
RETRACTED ARTICLE: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
Hany M Dabbous, Sherief Abd-Elsalam, Manal H El-Sayed, Ahmed F Sherief, Fatma F S Ebeid, Mohamed Samir Abd El Ghafar, Shaimaa Soliman, Mohamed Elbahnasawy, Rehab Badawi, Mohamed Awad Tageldin
Archives of Virology, doi:10.1007/s00705-021-04956-9
No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID-19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation. Identifier NCT04351295.
Compliance with ethical standards
Abd-Elsalam, Elkadeem, Glal, Chloroquine as chemoprophylaxis for COVID-19: Will this work?, Infect Disord Drug Targets, doi:10.2174/1871526520666200726224802
Abd-Elsalam, Esmail, Khalaf, Tanta protocol for management of COVID-19. Perspectives from a developing country, Endocr Metab Immune Disord Drug Targets, doi:10.2174/1871530320999201117142305
Abena, Chloroquine and hydroxychloroquine for the prevention or treatment of COVID-19 in Africa: caution for inappropriate off-label use in healthcare settings, Am J Trop Med Hyg
Arab-Zozani, Hassanipour, Ghoddoosi-Nejad, Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials, BMJ Open
Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: an open-label control study, doi:10.1016/j.eng.2020.03.007
Cascella, Rajnik, Cuomo, Features, evaluation and treatment coronavirus (COVID-19
Doi, Ikeda, Hayase, Nafamostat mesylate treatment incombination with favipiravir for patients critically ill with Covid-19: a case series, Crit Care
Du, Chen, Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clin Pharmacol Ther
Faul, Erdfelder, Lang, A flexible statistical power analysis program for the social, behavioral, and biomedical sciences, Behav Res Methods
Furuta, Mechanism of action of T-705 against influenza virus, Antimicrob Agents Chemother
Goldhill, Velthuis, Fletcher, The mechanism of resistance to favipiravir in influenza, Proc Natl Acad Sci
Hernandez, Roman, Pasupuleti, Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review, Ann Intern Med
Inoue, Jinno, Ohta, Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD, Respir Med Case Rep
Irie, Nakagawa, Fujita, Pharmacokinetics of favipiravir in critically Ill patients with COVID-19, Clin Transl Sci
Madelain, Oestereich, Graw, Ebola virus dynamics in mice treated with favipiravir, Antiviral Res
Marjot, Moon, Cook, Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study, J Hepatol, doi:10.1016/j.jhep.2020.09.024
Mohamed, Mohamed, Mohamoud, SARS-CoV-2: the path of prevention and control, Infect Disord Drug Targets, doi:10.2174/1871526520666200520112848
Noda, Shirai, Nakajima, Case report: two cases of COVID-19 pneumonia including use of favipiravir
Oestereich, Lüdtke, Wurr, Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res
Sarin, Choudhury, Lau, Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study), Hepatol Int, doi:10.1007/s12072-020-10072-8
Xie, Chen, Insight into 2019 novel coronavirus-an updated intrim review and lessons from SARS-CoV and MERS-CoV, Int J Infect Dis, doi:10.1016/j.ijid.2020.03.071
Yazdany, Kim, Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know, Ann Intern Med
Yin, Wunderink, MERS, SARS and other coronaviruses as causes of pneumonia, Respirology
Yokoyama, Oguri, Kato, Case report a case of COVID-19 pneumonia that did not worsen and was relieved by early administration of favipiravir and ciclesonide
Zhu, Chen, Gorshkov, Elfiky AA (2020) SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective, SLAS DIS-COV Adv Sci Drug Discov, doi:10.1080/07391102.2020.1761882
Zhu, Zhang, Li, Yang, Song, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop